ReviewCurrent drug targets2019
Saccharomyces cerevisiae (Baker's Yeast) as an Interfering RNA Expression and Delivery System.
Review in Current drug targets, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 62 citations in OpenAlex.
- Mosquito-based malaria control through genetic, microbial and immunological innovations.Nature reviews. Microbiology · 2026Review
- RNAi Power Targets in Insect Pests: Beyond Functional Validation to Biopesticide Development Potential.Plants (Basel, Switzerland) · 2026Review
- Effects of microparticle composition on colony morphology and viability of encapsulated therapeutic yeast for oral delivery.RSC pharmaceutics · 2026Article
- Advances in male sex separation for the support of mosquito control programs.Frontiers in insect science · 2026Review
- Development of an eco-friendly RNAi yeast attractive targeted sugar bait that silences the shaker gene in spotted-wing drosophila, Drosophila suzukii.Pest management science · 2026Article
- Developments and food safety considerations concerning genetically engineered microbial crop protection agents and biostimulants.Journal of pesticide science · 2025Article
- Control of Aedes albopictus populations by silencing of the vesicular GABA transporter (vgat) and the vesicular monoamine transporter (vmat) genes using recombinant Chlorella shRNA.Parasites & vectors · 2025Article
- Yeast Oral Delivery of DAF16 shRNAs Results in Effective Gene Silencing inCurrent issues in molecular biology · 2025Article
- Regulation of Plant Genes with Exogenous RNAs.International journal of molecular sciences · 2025Review
- Article
- Development of a controlled-release mosquito RNAi yeast larvicide suitable for the sustained control of large water storage containers.Scientific reports · 2024Article
- RNAi-Based Approaches to Control Mycotoxin Producers: Challenges and Perspectives.Journal of fungi (Basel, Switzerland) · 2024Review
- Characterization of a novel RNAi yeast insecticide that silences mosquito 5-HT1 receptor genes.Scientific reports · 2023Article
- Targeting Mosquitoes through Generation of an Insecticidal RNAi Yeast Strain Using Cas-CLOVER and Super PiggyBac Engineering inJournal of fungi (Basel, Switzerland) · 2023Article
- Review
- Outlook on RNAi-Based Strategies for ControllingPathogens (Basel, Switzerland) · 2023Review
- RNA Vaccines: Yeast as a Novel Antigen Vehicle.Vaccines · 2023Review
- Maximizing the Potential of Attractive Targeted Sugar Baits (ATSBs) for Integrated Vector Management.Insects · 2023Review
- RNAi turns 25:contributions and challenges in insect science.Frontiers in insect science · 2023Review
- Enhancing the Effect of Nucleic Acid Vaccines in the Treatment of HPV-Related Cancers: An Overview of Delivery Systems.Pathogens (Basel, Switzerland) · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The broad application of RNA interference for disease prevention is dependent upon the production of dsRNA in an economically feasible, scalable, and sustainable fashion, as well as the identification of safe and effective methods for RNA delivery. Current research has sparked interest in the use of Saccharomyces cerevisiae for these applications. This review examines the potential for commercial development of yeast interfering RNA expression and delivery systems. S. cerevisiae is a genetic model organism that lacks a functional RNA interference system, which may make it an ideal system for expression and accumulation of high levels of recombinant interfering RNA. Moreover, recent studies in a variety of eukaryotic species suggest that this microbe may be an excellent and safe system for interfering RNA delivery. Key areas for further research and development include optimization of interfering RNA expression in S. cerevisiae, industrial-sized scaling of recombinant yeast cultures in which interfering RNA molecules are expressed, the development of methods for largescale drying of yeast that preserve interfering RNA integrity, and identification of encapsulating agents that promote yeast stability in various environmental conditions. The genetic tractability of S. cerevisiae and a long history of using this microbe in both the food and pharmaceutical industry will facilitate further development of this promising new technology, which has many potential applications of medical importance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.